HealthDay News — In a report issued Tuesday, the US Food and Drug Administration acknowledged numerous shortcomings in its response to the infant formula shortage earlier this year.

“For things that are critical to the public health, if you don’t have some understanding of how all the pieces fit together, then when you get into a crisis or a shortage you have a real problem,” FDA Commissioner Robert Califf, MD, told the Associated Press. “To a large extent, that’s what happened here.”

Among the problems highlighted in the report were outdated data-sharing systems, while staffing and training for food inspectors was below normal. The agency also had poor insight into the supply chains and manufacturing procedures for infant formula.


Continue Reading

The 10-page report comes 8 months after the agency closed the Abbott infant formula plant in Michigan amid safety concerns and reports of illness in infants. The review was led by a senior official who interviewed roughly 60 agency employees. Although a whistleblower had tried to warn the FDA about problems in September 2021, the agency did not investigate until the following February. By then, 4 infants were ill and 2 had died. The FDA is still investigating whether there is a connection between those infants and the formula, the AP reported.

Mail delays were one of the reasons the FDA did not learn about the complaint earlier, according to information the agency gave Congress. Another was a failure to escalate the whistleblower allegations. The agency’s “inadequate processes and lack of clarity related to whistleblower complaint” likely contributed to delays, according to the report.

Shipping issues experienced by “third party delivery companies” further caused delays in testing bacterial samples, and the agency struggled with its testing capacity for the rare but potentially deadly Cronobacter bacteria that was linked to the infant formula outbreak. Still more issues were caused by the pandemic, both when the agency missed inspections after removing inspectors from the field and also because of COVID-19 cases among agency staff, the report said.

The report also asked for funding from Congress to improve infant formula inspections and standards. This would increase funding and hiring authority for new experts in the FDA food division, as well as improve technology to share data on FDA inspections, consumer complaints, and testing results.

Associated Press Article